Skip to content
High Tech Series A Founded 2015

NH TherAguix

NH TherAguix is a biotechnology company developing nanoparticle-based theranostic products for cancer treatment. Its lead product, AGuIX, is a theranostic nano-drug designed to improve the efficacy of radiotherapy for cancer patients. The company has developed a pipeline of drugs targeting brain metastases, lung cancer, pancreatic cancer, and cervical cancer. The theranostic approach combines therapeutic and…

📍 Lyon, France · Nanotechnology,

Funding snapshot

Last roundSeries A
Amount$15M
Date11 April 2019
Total raised$16M
Team size6

About

NH TherAguix is a biotechnology company developing nanoparticle-based theranostic products for cancer treatment. Its lead product, AGuIX, is a theranostic nano-drug designed to improve the efficacy of radiotherapy for cancer patients. The company has developed a pipeline of drugs targeting brain metastases, lung cancer, pancreatic cancer, and cervical cancer. The theranostic approach combines therapeutic and diagnostic capabilities within a single nanoparticle, enabling simultaneous treatment and imaging of Founded in 2015 and headquartered in Lyon, France, the company has raised $15.9M in Series A funding from investors including Bpifrance, Supernova Invest, Financiere Arbevel, and Omnes Capital.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,

Oncology > Drugs > Diversified

Institutional investors

Bpifrance Supernova Invest Financiere Arbevel Omnes Capital

Latest coverage

No articles yet.

Raising like NH TherAguix?

Analyze your pitch deck before your next raise.

Analyze My Deck →